Serina Therapeutics advances SER-252 Parkinson’s registrational study to Cohort 2 after safety review
SER•Topline results expected in 2027
Topline results from the single-ascending-dose portion are expected in the first half of 2027.
SER•SER•SER•Topline results from the single-ascending-dose portion are expected in the first half of 2027.
Serina Therapeutics advanced SER-252 into Cohort 2 of its Phase 1b registrational study in advanced Parkinson’s disease.
Blinded Cohort 1 review supported continued dose escalation, with observations consistent with sustained drug exposure and motor improvement in some patients.
